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Abstract 
 
Introduction: Lung Cancer is the leading cause of cancer death in the United States and 
Western Europe. Small cell lung cancer (SCLC) accounts for up to 13% of all newly 
diagnosed lung cancers. The knowledge of factors that could predict the clinical outcome 
of patients with SCLC is important for guiding treatment and to determining prognosis.  
Imunohistochemical study by the analysis and characterization of markers involved in 
SCLC could improve the knowledge of prognostic factors. The purpose of this article is 
to investigate the prognostic value of six Imunohistochemical Markers in patients with 
SCLC diagnosis: Chromogranin A (Chromo A), Cytokeratin 7 (CK7), Thyroid 
transcription factor-1 (TTF-1), Neural cell adhesion molecule/CD56, Ki-67 (MIB1) and 
High weight cytokeratin (LP34).  
 
Material and Methods: Patients had a histological confirmed small-cell lung cancer 
(SCLC) diagnosed at our University Hospital between February 2002 and December of 
2008 and a total of 100 cases (13 women, 87 men) were selected for this study.  
 
Results: The mean survival of all patients was 274 days (9months), and median was 183 
days (6months). The survival mean for LD-SCLC was 482 days (16months, with a 95% 
Confidence Interval from 10 months to 22 months) and 182 days for ED-SCLC 
(6months, with a 95% Confidence Interval from 4 months to 8 months). 
The patients showed a significant meaning in Chromo A curves isolated, with a mean of 
Survival with the group expressing A of 6,7 months and 11 months in the group 
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expressing B. Tumors that expressed Chromo A (B) & CD56 (A) had the best prognosis 
with a survival mean of 726 days (24,2months) against 234 days (7,8 months). The worst 
prognosis was for the combination of CD56 (B) + Ki67 (B) with a survival mean of 6 
months against 11 months for the rest of the patients. 
 
Conclusion: Based on those considerations, we hypothesize that Chromo A isolated 
could be a prognostic factor of survival. Patients that show Chromo A (B) & CD56 (A) 
had a very good prognosis with a mean of survival of 726 days. On other hand, patients 
that show CD56 (B) + Ki67 (B) had a poor prognosis with a mean of survival of 6 
months.  
 
Keywords: small cell lung cancer, prognostic factors, Imunohistochemical Markers, 
Ki67, LP34, CK7, Chromo A, CD56, TTF1.  
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Introduction  
 
Lung Cancer is the malignant leading cause of death in the United States and Western 
Europe by Cancer. Small cell lung cancer (SCLC) accounts for up to 13% of all newly 
diagnosed lung cancers and is strongly associated with cigarette smoking. It differs from 
other types of lung cancer in its propensity for early systemic spread and its aggressive 
clinical course if left untreated. (1, 2) 
Together with melanoma it is considered, one of the most aggressive tumors accounting 
with a survival mean ranging from 2 to 4 months without treatment. With currently 
available chemotherapy, the survival mean for patients with LD-SCLC (limited stage 
disease SCLC), ranges from 16 months to 26 months. Patients with tumors that have 
metastasized to contralateral supraclavicular nodes, cytology-proven malignant pleural or 
pericardial effusion are staged as extensive-stage disease SCLC (ED-SCLC), and the 
mean survivals varies from 6 months to 12 months. (3-6) 
It was demonstrated previously that good performance status (PS), young age, being a 
woman and limited stage disease are associated with an improved prognosis. Other 
variables like liver metastasis, low albumin levels, and low sodium levels have been 
associated with a poor prognosis.  (7-13) 
Compared with other cell types of lung cancer SCLC has different biological behaviors. 
The knowledge of factors that could predict the clinical outcome of patients with SCLC is 
important for guiding treatment and to determining prognosis.  
Imunohistochemical study by the analysis and characterization of markers involved in 
SCLC could improve the knowledge of prognostic factors. The six imunohistochemical 
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markers used in this trial were: Chromogranin A (CromoA), Cytokeratin 7 (CK7), 
Thyroid transcription factor-1 (TTF-1), Neural cell adhesion molecule/CD56, Ki-67 
(MIB1) and High weight cytokeratin (LP34).  
Chromogranin A (Chromo A) is an acidic glycoprotein belonging to a family of regulated 
secretory proteins stored in the dense core granules of the adrenal medulla and of many 
other neuroendocrine cells and neurons. The role of Chromo A is not known precisely, 
but possible functions include intracellular regulation of the formation of neuroendocrine 
granules, regulation of hormone secretion and function as a pro-hormone. (14) 
Cytokeratins (CK) are soft epithelial intermediate filaments that comprise approximately 
20 different Keratin polypeptides. This family of intermediate filaments is found to be 
crucial in the diagnostic immunohistochemistry and for identification of specific 
carcinoma subtypes. Cytokeratin 7 (CK7) is a simple keratin that has restricted 
distribution in many simple, stratified and ductal epithelium, such as breast, ovary, lung, 
uterus and neuroendocrine cells. (15) 
Monoclonal antibody 34betaE12 (or LP34) recognizes a set of cytokeratins (1, 5, 10, 14) 
expressed in normal stratified squamous epithelium. Some trials have recently reported 
its expression in squamous cell carcinoma and basaloid carcinoma, in contrast to large 
cell neuroendocrine carcinoma, an entity with overlapping morphological features with 
basaloid carcinoma.  
Thyroid transcription factor-1 (TTF-1) is a tissue specific homeodomain containing 
DNA-binding proteins of the Nkx-2 gene family. It plays an important role in the early 
differentiation and morphogenesis of the developing brain, lung and thyroid. In lungs, it 
activates the promoters for Clara cell secretory protein, and surfactant apoproteins. 
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Different percentages in TTF-1 nuclear expression are of clinical importance to 
distinguishing different histological types of lung carcinoma and it is still incompletely 
understood its high expression in SCLC.  (16) 
Neural cell adhesion molecule/CD56 is specifically expressed by neural, peripheral 
neuroectodermal and neuroendocrine tissues and tumors. It belongs to the 
immunogloblulin family of cell surface adhesion proteins involved in direct cell-cell 
adhesion. CD56 is also found in natural killer cells, natural killer-like T cells, myocites, 
and seromucous glands. (17) 
Ki-67 antigen in tumor cell reflects the expression of a DNA-binding nuclear protein 
encoded by a gene in chromosome 10. Moreover, it is known that Ki6 expression is a 
molecular marker of tumor proliferation, and its over-expression has been linked to a 
poorer prognosis in NSCLC. (18) 
The purpose of this work was to investigate the prognostic value of the described 
Imunohistochemical Markers, usually applied in daily routine of SCLC diagnosis.   
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 Material and methods 
 
Human Subject 
Patients had a histological confirmed small-cell lung cancer (SCLC) diagnosed at our 
University Hospital between February 2002 and December of 2008 and a total of 100 
cases (13 women, 87 men) were selected for this study.  
All patients who were ineligible for absence of survival register and were alive with a 
survival period bellow one year were excluded. Histological diagnosis was made 
according to the World Health Organization guidelines. The following clinical variables 
were registered: age at diagnosis time, symptoms that lead to diagnosis, smoking history, 
extension of disease (ED-SCLC and LD-SCLC), pathological antecedents and survival.  
The mean age of diagnosis was 65 years (range, 27-83 years). 
The survival time was defined as the interval in days beginning with the histological 
diagnosis and death or last recorded follow-up. From the 100 patients 5 were alive on the 
15th of September 2009 and their survivals were over 24 months. 
  
Tissue Analysis - Immunohistochemistry 
Three µm sections of TMA were placed on coated slides and were allowed to dry 
overnight. After deparaffinization and rehydration, antigen unmasking was performed 
using pronase E on LP34 and CK7 markers, using Module PT for Citrate buffer in 
Chromo A and Module PT for EDTA buffer in TTF1 and Ki67, for 10 minutes. 
Endogenous peroxidase activity was quenched using 15 minutes incubation in 3% 
diluated hydrogen peroxidase (H2O2). For blocking nonspecific binding of secondary 
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antibody, Ultra V Block (Ultra vision Kit; TP-015-HL; LabVision) was applied to the 
sections and then the sections were incubated at room temperature with primary 
antibodies against clone 123C3, DAKO – CD56; clone LP34, Novocastra – LP34; clone 
DV-TL 12/30, DAKO – CK7; clone DAK-A3, DAKO – Chromo A; clone 8G7G3/1, 
DAKO – TTF1 and clone MIB-1, Dako – Ki67 at a dilution of: 1:100 to CD56 for 30 
minutes; 1:100 for 60 minutes to LP34; 1:50 for 30 minutes to CK7; 1:300 for 30 minutes 
for Chromo A; 1:100 for 60 minutes for TTF1 and 1:50 for 30 minutes to Ki67.  After 
washing with phosphate –buffered saline (PBS) the slides were incubated with biotin-
labeled secondary antibody for 30 minutes. Primary antibody biding was localizated in 
tissues using peroxidase-conjugated streptavidin (LabVision) and 3-3diaminobenzidine 
tetrahydrochloride (DAB) was used as the chromogen, according to manunfacturer’s 
instructions. The slides were counterstained with hematoxylin, dehydrated and mounted. 
In parallel we used known positive controls and negative controls.  
Each imunohistochemical anthibody was validated according with two variables, A and 
B, that correspond to 0-25% of cells expressing the antibody – A, and >25% of cells with 
positivity - B.   
 
Statistical Analysis  
The statistical analysis was performed with SPSS Version18.0. Lifetable probabilities of 
overall survival were performed by the Kaplan–Meier method (Kaplan and Meier, 1958), 
and differences in survival between subgroups of patients were compared with the log-
rank test (Mantel, 1996). A P-value < 0.05 was considered significant. 
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Results 
 
This study included 100 (13 women and 87 men) patients diagnosed with Small Cell 
Lung Cancer at Coimbra University Hospital between 2002 and 2008. The mean age of 
diagnosis was 65 years.  
Of the 100 patients, only 80 (11 women and 69 men) had register of smoking history. 
Fifteen were non smokers (10 women) and the other 65 (81%) were smokers with a mean 
of 61,3 pack-years. (Fig.1)  
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Fig. 1 – Distribution of gender by Smoking History. 
 
The most frequent symptoms in 93 patients were cough (28,0%) dyspnea (29,8%), 
asthenia (23,8%) and anorexia (18,3%); incidental finding happened in 18,3%. (Table I 
and Fig.2). 
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Table I – Symptoms: Most of the patients have more than one symptom.   
 
S ymptoms
48%
23%
9%
8%
12% R es piratory S imptoms
S is temic  S ymptoms
Neurological
S ymptoms
Inc identaloma
Others
 
Fig.2 – Symptoms distributed by groups.  
Symptoms n % Symptoms n % 
Cough 26 28,0 Muscle weakness (lower members) 2 2,2 
Dyspnea 24 25,8 Painful cervical mass 2 2,2 
Asthenia 18 19,4 Hoarseness 2 2,2 
Anorexia 17 18,3 Pleural effusion 2 2,2 
Incidentaloma  17 18,3 Paresthesia (left arm) 1 1,1 
Chest pain 16 17,2 Pleuritic Chest pain 1 1,1 
Hemoptysis 13 14,0 Aphasia 1 1,1 
Flu syndrome 12 12,9 Wheeze 1 1,1 
Weight loss 11 11,8 Loss of vision 1 1,1 
Osteoarticular pain 5 5,4 Nausea 1 1,1 
Dysphagia 5 5,4 Paresthesia (lower member) 1 1,1 
Headache 4 4,3 Arm edema 1 1,1 
Disequilibrium 3 3,2 Abdominal Pain 1 1,1 
Pneumonia  3 3,2 Disorientation 1 1,1 
Dysphonia 2 2,2 Atelectasis 1 1,1 
Orthopnea 2 2,2 Vomitus 1 1,1 
Diabetes insipidus 2 2,2 Anemia  1 1,1 
Vertigo 2 2,2 Adenopatias axilares 1 1,1 
Muscle weakness 2 2,2 Sudden paraplegia below D12  1 1,1 
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The more common pathological antecedent was HTA (19 in 79 patients) followed by 
absence of pathological antecedents (15 patients). 
P atholog ic al Antec edents
2% 2%
2%
2%
3%
3%
3%
3%
3%
3%
4%
5%
10%
12%
43%
Lumbar Disc Hernia
Benign Prostatic
Hyperplasia
Cardiac Insufficiency
Stroke
Colecistectomy
Paludism
Acute M yocardial
Infarction
Chronic obstructive
pulmonary disease
Herniorrafy
Appendicectomy
Pneumonia
Diabetes
No Patho logical
Antecedents
High Blood Pressure
others (with only 1 or 2
cases)
 
Fig. 3 – Pathological Antecedents.  
The mean survival of all patients was 274 days (9months), and median was 183 days 
(6months); 34 patients remained alive after 274 days survival. (Table II, Fig.4, Fig. 5).  
Means and Medians for Survival Time 
  Mean Median 
Estimate Std. Error 
95% Confidence 
Interval 
Estimate Std. Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
Survival 273.840 33.814 207.564 340.116 183.000 21.000 141.840 224.160 
Table II – Means and Medians for Survival  
 
 12
 
 
 
 
 
 
Fig.4 – Percentage of Patients Survival with SCLC 
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Fig.5 – Distribution of Survival Days by semesters. 
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Fig. 6 – Survival of all patients. Cum Survival (Cumulative Survival – Percentage). 
Survival by days.  
 
The evaluation of prognostic value of gender is defined in Fig.7 and the overall 
comparison of Clinical parameters is described in Table III. The relation between age and 
survival can be seen in Fig. 8, which represents the relation of curves between the 
population with age bellow 70 years and population above 70 years. That division of age 
was the most significant if compared with division between lower and upper 65 years, 60 
years, and 75 years. The relation between extension of disease and survival is in Fig. 9, 
and the significance of those curves in Table III 
 
.  
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Overall Comparisons 
Log Rank (Mantel-Cox)         Chi-Square df Sig. 
Gender (Female vs Male) .082 1 .775 
Age (<70 & >70) 2.136 1 .144 
Extension 13.351 1 .000 
Table III - Test of equality of survival distributions for the different factors. 
Sig – Significance (P value). 
 
Fig. 7 – Survival Curves by Gender. Cum Survival (Cumulative Survival – Percentage). 
Survival by days. 
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Fig. 8 – Survival Curves by Age. Upper and lower 70 years.  
 
  
 
Fig. 9 – Survival Curves by Extension of SCLC. ED-SCLC (Extensive disease of Small 
Cell Lung Cancer) LD-SCLC (Limited Disease of Small Cell Lung Cancer). 
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Extensive disease was the only factor that demonstrated significant difference for 
survival: the survival mean for LD-SCLC was 482 days (16months, with a 95% 
Confidence Interval from 10 months to 22 months) and 182 days for ED-SCLC 
(6months, with a 95% Confidence Interval from 4 months to 8 months). The median 
value of survival for LD-SCLC was 383 (12.7) months and 169 (5.6months) for ED-
SCLC.  
 
Table IV – Means and Medians for LD-SCLC and ED-SCLC.  
 
 
 
 
 
 
 
 
 
 
Table V – Survival means and Confidence Intervals (days) 
 
 
Means and Medians for Survival Time 
Extension 
Mean Median 
Estimate Std. Error 
95% Confidence 
Interval (days) 
Estimate Std. Error 
95% Confidence 
Interval (days) 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
LD-SCLC 481.833 92.904 299.741 663.925 383.000 22.274 339.343 426.657 
ED-SCLC 182.464 25.083 133.301 231.627 169.000 14.343 140.888 197.112 
Overall 255.284 32.766 191.062 319.506 193.000 17.742 158.225 227.775 
Survival Means and range  
 
95% Confidence 
Interval (days) 
 Mean 
Lower 
Bound 
Upper 
Bound 
Gender (Female vs Male)  
Female 256.308 80.779 431.836 
Male 276.460 204.576 348.343 
Age (<70 & >70)  
<70 years 308.825 219.232 398.419 
>70 years 216.583 121.866 311.301 
Extension  
LD-SCLC 481.833 299.741 663.925 
ED-SCLC 182.464 133.301 231.627 
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The distribution of Markers Expression in all group (100 patients) is related on Table VI.  
Case Processing Summary 
CK7 LP34 CromoA TTF1 Ki67 CD56 
 N  n  n  n   n   n 
A 57 A 98 A 43 A 30 A 14 A 20 
B 43 B 2 B 57 B 70 B 86 B 80 
Overall 100 Overall 100 Overall 100 Overall 100 Overall 100 Overall 100 
Table VI - Distribution of Markers Expression. A – less then 25% positive cells 
expression; B – 25% to 100% positive cells expression.  
 
The value of significance in survival distributions for the different Imunohistochemical 
(IMC) Markers is described in table VII. This value expresses the difference between the 
two curves of survival (A and B). Each curve corresponds to a variable A or B in one 
Imunohistochemical Marker.  
 
 
 
 
 
 
Table VII - Test of equality of survival distribution for the different antibodies. 
Overall Comparisons 
Log Rank (Mantel-Cox)         Chi-Square df Sig. 
CK7 .572 1 .450 
LP34 .036 1 .850 
CromoA 3.575 1 .059 
TTF1 .585 1 .444 
Ki67 .625 1 .429 
CD56 1.466 1 .226 
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.  
Table VIII - Means and Medians for population expressing A and B for Chromo A. 
When we evaluate all variables (A and B) in each IMQ Mark we only found statistically 
meaning for Chromo A.  The Fig. 10, 11, 12, 13, 14 and 15 shows the survival 
distribution of variables in each Mark. 
 
 
Fig. 10 – Survival Curves in CK7 
Means and Medians for Survival Time 
ChromoA Meana Median 
Estimate 
Std. 
Error 
95% Confidence Interval 
Estimate 
Std. 
Error 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Lower 
Bound 
Upper 
Bound 
A 202.488 30.557 142.596 262.381 175.000 19.011 137.738 212.262 
B 327.667 53.829 222.161 433.172 193.000 45.831 103.171 282.829 
Overall 273.840 33.814 207.564 340.116 183.000 21.000 141.840 224.160 
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Fig. 11 – Survival Curves in LP34. 
 
Fig. 12 – Survival Curves in CromoA.  
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Fig. 13 – Survival Curves in TTF1. 
 
 
Fig. 14 – Survival Curves in Ki67 
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Fig. 15 – Survival Curves in CD56. 
 
Combinations between two Imunohistochemical Markers were applied to avoid less then 
5 cases per antibody and their significance is in Table IX. Each relation was established 
between a curve expressed by the group with the condition (C - combination between two 
Markers) and the curve formed by the rest of patients survival (D).  
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Overall Comparisons - Log Rank (Mantel-Cox) 
Marks Combination Sig. Survival Mean nº Marks Combination Sig. 
Survival 
Mean nº 
CromoA 
(A) + 
CD56 (A) 0.087 D>C 12 
CD56 (B) 
+ 
Ki67 (A) 0.943 D=C 11 
CD56 (B) 0.331 D>C 31 Ki67 (B) 0.258 D>C 69 
Ki67 (A) 0.543 C>D 5 TTF1 (A) 0.232 C>D 24 
Ki67 (B) 0.018 D>C 38 TTF1 (B) 0.026 D>C 56 
TTF1 (A) 0.520 D>C 16 CK7 (A) 0.254 D>C 45 
TTF1 (B) 0.100 D>C 27 CK7 (B) 0.940 D=C 35 
CK7 (A) 0.355 D>C 26 LP34 (A) 0.264 D>C 79 
CK7 (B) 0.126 D>C 17 LP34 (B) - - 1 
LP34 (A) 0.064 D>C 41 Total Patients 80 
LP34 (B) - - 2 
Ki67 (A) 
TTF1 (A) 0.728 C>D 5 
Total Patients 43 TTF1 (B) 0.492 C>D 9 
CromoA 
(B) + 
CD56 (A) 0,007 C>>D 8 CK7 (A) 0.996 C=D 11 
CD56 (B) 0.866 D>C 49 CK7 (B) 0.199 C>D 3 
Ki67 (A) 0.630 C>D 9 LP34 (A) 0.429 C>D 14 
Ki67 (B) 0.138 C>D 48 LP34 (B) - - 0 
TTF1 (A) 0,131 C>D 14 Total Patients 14 
TTF1 (B) 0.550 C>D 43 
Ki67 (B) 
TTF1 (A) 0.532 C>D 25 
CK7 (A) 0.981 C=D 31 TTF1 (B) 0.239 D>C 61 
CK7 (B) 0.05 C>D 26 CK7 (A) 0.448 D>C 46 
LP34 (A) 0.05 C>D 57 CK7 (B) 0.875 C=D 40 
LP34 (B) - - 0 LP34 (A) 0.487 D>C 84 
Total Patients 57 LP34 (B) - - 2 
CD56 (A) 
+ 
Ki67 (A) 0.225 C>D 3 Total Patients 86 
Ki67 (B) 0.542 C>D 17 
TTF1 (A) 
CK7 (A) 0.492 D>C 19 
TTF1 (A) 0.381 D>C 6 CK7 (B) 0.089 C>D 11 
TTF1 (B) 0.077 C>D 14 LP34 (A) 0.358 C>D 28 
 
CK7 (A) 
 
0.608 
 
C>D 
 
12 LP34 (B) - - 2 
CK7 (B) 0.283 C>D 8 Total Patients 30 
LP34 (A) 0.225 C>D 19 
TTF1 (B) 
CK7 (A) 0.808 D>C 38 
LP34 (B) - - 1 CK7 (B) 0.598 D>C 32 
Total Patients 20 LP34 (A) 0.492 D>C 69 
CK7 (A) 
LP34 (A) 0.450 D>C 57 LP34 (B) - - 1 
LP34 (B) - - 0 Total Patients 70 
Total Patients 57 
 
 
   
CK7 (B) 
LP34 (A) 0.418 C>D 41     
LP34 (B) - - 2   
Total Patients 43    
 
Table IX - Test of equality of survival distributions for the different factors. C – condition (combination of two 
markers); D – the other patients that doesn’t verify the condition C. 
Nº - number of patients which verify the condition C in all 100 patients.; 
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Survival Mean 
Combination Marks Sig. Patients Group Estimate Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
CromoA (A) + CD56 (A) 
 
0.087 
 
C 149.750 41.257 68.886 230.614 
D 290.761 37.706 216.857 364.665 
CromoA (A) + Ki67 (B) 0.018 C 182.789 27.742 128.416 237.163 
D 329.645 50.720 230.233 429.057 
CromoA (A) + LP34 (A) 0.064 C 201.195 32.009 138.458 263.932 
D 324.322 52.055 222.295 426.349 
CromoA (B) + CD56 (A) 0,007 C 726.500 206.453 321.852 1131.148 
D 234.478 29.226 177.196 291.761 
CromoA (B) + CK7 (B) 0.05 C 391.231 95.846 203.372 579.089 
D 232.595 30.007 173.780 291.409 
CromoA (B) + LP34 (A) 0.05 C 327.667 53.829 222.161 433.172 
D 202.488 30.557 142.596 262.381 
CD56 (A) + TTF1 (B) 0.077 C 473.286 141.072 196.784 749.787 
D 241.372 31.055 180.504 302.240 
CD56 (B) + TTF1 (B) 0.026 C 200.804 24.155 153.460 248.147 
D 366.795 68.368 232.794 500.797 
TTF1 (A) + CK7 (B) 0.089 C 469.455 175.029 126.399 812.511 
D 249.663 30.897 189.104 310.222 
Table X – Combinations with significance and closed to significance meaning with their 
survivals and CI means. Blue – better prognosis; Orange – worse prognosis 
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Fig.16 – Survival Curves of Population expressing CromoA B + CD56 A – (C) and rest 
of the patients (D). 
  
Fig.17 – Survival Curves of Population expressing CromoA A + Ki67 B – (C) and rest of 
the patients (D). 
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Discussion  
Small Cell Lung Cancer remains an incurable disease for the majority of patients with a 
poor prognostic survival as demonstrated in this study as for the best of our knowledge is 
the first work trying to relate cell immunohistochemical characteristics and survival.  
Extended disease was associated with significantly worse outcomes with a very 
significant value (0.000). The mean of survival with a LD-SCLC was 482 days 
(16months with a 95% Confidence Intervals from 10 months to 22 months) and survival 
mean in ED-SCLC was 182 days (6months with a 95% CI from 4 months to 8 months), 
slightly different from other reports. Nathan F. Sumithra J. et al (3) had a mean ranged 
from 17.2 months to 26.4 months for LD-SCLC trials and from 2.6 months to12.3 months 
for ED-SCLC trials. On the other hand extent of disease has traditionally been used for 
prognostic stratification of patients with SCLC. The current study demonstrated that 
staging which was named limited or extensive disease remains the most powerful 
prognostic factor for SCLC.  (19) 
Increased patients age and “being a man” was not associated with a better survival in this 
group of population and age curve had the most significant value for the two curves by 70 
years. Female gender is another commonly described prognostic factor in SCLC (3). In 
the present analysis a different survival outcome related to gender could not be found.   
In this trial SCLC was associated with male gender (87%), 65 years mean age and 81% 
of the patients were smokers with heavy smoking history (mean 61,3 pack-years). From 
the 13 women included only one was smoker and only five men were not smokers 
indicating the possible relation between smoking history and SCLC already described in 
other works. 
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As a large number of patients were diagnosed without symptoms the aggressive behavior 
of SCLC is explained as a silent disease till later stages. 
A survival mean value of 274 days (9months) was determined, and median of 183 days 
(6months) for the whole population. According to Fig. 4 the upper and lower quartile 
were 37 days and 359 days, closed to mean value, but the range of survival values is very 
large. Most of the patients die in 12 months (76%) Fig 5. This work provides prognostic 
factors that at time of diagnosis could predict a better survival.  
The six IMC Markers were applied to all 100 patients and divided in two variables: A – 
cellular expression till 25% of cells, and B – more than 25% of positive. The curves of A 
and B for each IMC Marker were compared individually in order to find difference 
influence in survival time of the patients that expressed B against A. Those curves were 
analyzed statistically and are exposed in Table VII. The patients showed a significant 
meaning in Chromo A curves isolated, with a mean of Survival with the group expressing 
A of 6,7 months and 11 months in the group expressing B. According to Drivsholm L.  
Paloheimo LI. and Østerlind K. (20):  Survival in SCLC is significantly worse for 
patients with elevated Chromo A serological values and Chromo A is a significant 
prognostic factor – also in multivariable analysis. This study was not made with 
serological values of Chromo A but according to our results Imunohistochemical analysis 
of Chromo A in SCLC could be an indicator of good prognosis in SCLC. 
Tumors that expressed Chromo A (B) & CD56 (A) had the best prognosis with a survival 
mean of 726 days (24,2months) against 234 days (7,8 months), better than the actual 
known survival of LD-SCLC. The worst prognosis was for the combination of CD56 (B) 
+ Ki67 (B) with a survival mean of 6 months against 11 months for the rest of the 
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patients. Other combinations were also statistically significant. Cases expressing CD56 
(B) & TTF1 (B) had worse prognosis with a survival mean of 6,7 months against 12 
months; and the combination of Chromo A (B) & CK7 (B) had an improved in survival 
time with mean of 13 months against 7,7 months for the rest of the patients. 
It was clearly demonstrated that neuroendocrine differentiation based in Chromo A 
expression by tumor cells indicates an higher survival as showed in this statistical study. 
The cases expressing Chromo A in more than 25% of cells have improved survival when 
compared to B group (less than 25% of positive cells). The best survival curve was seen 
in Chromo A (B) & CD56 (A). Our results are consistent with previous studies that 
showed CD56 role in cell surface adhesion, making its expression related to bad 
prognosis. (17) The combination of “no expression” of CD56 – A - and highly expressed 
ChromoA – B - makes the best survival time. Combination between Chromo A (B) and 
CK7 (A) also had a better survival; fact that could be explained by the relation of CK7 
and pulmonary adenocarcinomas improving the prognosis of this tumor. It is well 
reported the relation between CK7 and Adenocarcinomas and is also known the best 
prognosis of this tumor when compared with SCLC.  
Ki67 had a role in proliferation rate determination as explained in many previous works 
and related with worse outcomes in survival times of the patients expressing more then 
25% of positive cells. This fact could be the reason for CD56 (B) + Ki67 (B) worst 
prognosis. (18) 
The high expression of TTF1 tended to show better survival then TTF1 (-) group in non 
SCLC (21). That was not verified in this trial.    
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The utility of these 6 antibodies applied in routine diagnosis of SCLC, either by cytology 
in biopsies reinforces de utility of IBPCC (Immunohistochemical Bronchial Pulmonary 
Carcinoma Classification). It is a simple and efficient tool for streamlining the 
registration of lung cancer histological characteristics in biopsies and other reduced 
samples to support clinical evidence and trials. (22) 
 
 29
References 
 
1. Ries LAG. Harkins D. Krapcho M. Mariotto A. Miller BA. Feuer EJ. et al. SEER 
Cancer Statistics Review, 1975-2004. Lung Bronchus, Percent Distribution and 
Counts by Histology, 2001-2004, Both Sexes by Race, Table XV-23.  
2. Kakolyris S. Agelidou A. Androulakis N. Tsaroucha E. et al. Cisplatin plus 
etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus 
cisplatin consolidation therapy for patients with limited stage small cell lung 
carcinoma 2006; Lung Cancer (2006) 53, 59-65. 
3. Nathan R. Sumithra J. Steven E. et al. Prognostic factors Differ by Tumor Stage 
for Small Cell Lung Cancer. American Cancer Society 2009; 2721-2731 
4. Johnson BE. Bridges JD. Sobczeck M. et al. Patients with limited stage small-cell 
lung cancer treated with concurrent twice-daily chest radiotherapy and 
etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. 
1996; 14:806-813.  
5. Murray N. Coy P. Pater JL. et al. Importance of timing for thoracic irradiation in 
the combined modality treatment of limited-stage small cell lung cancer. The 
National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993; 
11:336-344. 
6. Turrisi AT. Kim K. Blum R. et al. Twice-daily compared with once-daily thoracic 
radiotherapy in limited small.cell lung cancer treated currently with cisplatin and 
etoposide. N. Engl J Med. 1999;340:265-271 
 30
7. Lassen U. Osterlind K. Hansen M. et al. Long term survival in small cell lung 
cancer: post treatment characteristics in patients surviving 5 to >18 years – an 
analysis of 1714 consecutive patients. J Clin Oncol. 1995; 13; 1215-1220. 
8. Albain KS. Crowley JJ. LeBlanc M. Livingston RB. Determinants of improved 
outcome in small cell lung cancer: an analysis of the 2580-patient Southwest 
Oncology Group data base. J Clin Oncol. 1990;8 1563-1574. 
9. Cerny T. Blair V. Anderson H. Bramwell V. Thatcher N. Pretreatment prognostic 
factors and scoring system in 407 small cell lung cancer patients . Int J Cancer, 
1987;39:146-149 
10. Rawson NS. Peto J. An overview of prognostic factors in small cell lung cancer. 
A report from de Subcommittee for the Management of Lung Cancer of the 
United Kingdom Coordinating Committee on Cancer Res. Br J Cancer. 1990; 
61:597-604. 
11. Sculier JP. Chansky K. Crowley JJ. Van Meerbeeck J. Goldstraw P. The impact 
of additional prognostic factors on survival and their relationship with the 
anatomical extent of disease expressed by the 6th edition of TNM Classification of 
malignant Tumors and the proposals for the 7th edition. J Thorac Oncol. 2008; 
3:457-466. 
12. Souhami RL. Bradbury I. Geddes DM. Spiro SG. Harper PG. Tobias JS. 
Prognostic significance of laboratory parameters measured at diagnosis in small 
cell carcinoma of the lung. Cancer Res. 1985;45:2878-2882. 
 31
13. Wolf M. Holle R. Hans K. Drings P. Havemann K. Analysis of prognostic factors 
in 766 patients with small cell lung cancer: the role of sex as a predictor for 
survival. Br J Cancer, 1991;63:986-992. 
14. Gregorc V. Spreafico A. Floriani I. Colombo B. e tal – Prognostic value of 
circulating Chromogranin A and soluble tumor necrosis factor receptors in 
Advanced nonsmall cell lung cancer. American Cancer Society 2007 845-853. 
15. Tarek G. Guoan C. Hong W. Proteomic Analysis of Cytokeratin Isoforms 
Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia 2002; 4 
(5): 440-448 
16. Loreto C. Lauro V. Puglisi F. Damante G. Fabbro D and Beltrami C. – 
Immunocytochemical expression of tissue specific transcription factor-1 in lung 
carcinoma. J. Clin Pathol 1997; 50:30-32 
17. Kontogianni K. Nicholson A. Butcher D. Sheppard M. – CD56: a useful tool for 
the diagnosis of small cell lung carcinomas on biopsies with extensive crush 
artefact. J Clin Pathol 2005; 58:978-980. 
18. Nguyen X. Lee W. Chung J. Park S. Sung S. Kim Y. So Y. et al – FDG uptake, 
glucose transporter type 1, and ki67 expression in non-small-cell lung cancer: 
correlations and prognostic values. European Journal of Radiology 2007; 62: 214-
219. 
19. Arinc S. Gonlugur U. Devran O. Erdal N. et al – Prognostic factors in patients 
with small cell lung carcinoma. Med Oncol 2009.   
 32
20. Drivsholm L. Paloheimo L. Østerlind K. - Chromogranin A, a significant 
prognostic factor in small cell lung cancer. British Journal of Cancer (1999); 
81(4), 667–671. 
21. Myong NH. – Thyroid Transcription Factor-1 (TTF1) expression in human lung 
carcinomas: its prognostic implication and relationship with expressions of p53 
and Ki67 proteins. J Korean Med Sci 2003; 18:294-500.  
22. Carvalho L. Reclassifying bronchial – pulmonary carcinoma: differentiating 
histological type in biopsies by immunohistochemistry. Rev Port. Pneumol 2009; 
15 (6):1101-1119.  
 
 
 
 
 
 
 33
Agradecimentos 
 
Os meus agradecimentos à Sra. Professora Doutora Lina Carvalho e à Sra. 
Dra. Alice Mariano Pêgo por toda a atenção e disponibilidade demonstrada no 
decorrer da elaboração do presente trabalho. 
 
 
 
 
